In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Pharmacogenomics Challenge

Executive Summary

Individualized drug therapy represents such a potential watershed in the pharmaceutical industry that drug and biotech players have no option but to consider how and when they should participate in pharmacogenomics. But thanks to the evolving nature of the technologies and responses to the cultural and political issues pharmacogenomics raises, drug firms should think in particular about three areas of opportunity and risk: enhancing the commercial value of drugs; regulatory changes that could lead to micro-segmentation of markets; and new methodologies that streamline clinical development costs.

You may also be interested in...

Gentris Corp.

Gentris Corp. is developing and commercializing proprietary clinical pharmacogenomic markers, initially for pharmaceutical customers but ultimately to offer as clinical diagnostics. Pharmacogenomics, it believes, can improve trial design, and increase predictability, shorten the drug development cycle, improve new drug approval rates, and enable companies to retest drug candidates that fail to meet clinical trial or FDA approval standards.

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts